Cellabs
Cellabs is a Sydney-based boutique biotechnology company specializing in the design, development, and manufacture of immunodiagnostic kits for tropical and infectious diseases. Established in 1985, it is Australia's oldest private biotech firm, with a focus on neglected tropical diseases such as malaria, leishmaniasis, elephantiasis, and schistosomiasis. Cellabs supplies diagnostic products worldwide, including assays for diseases like malaria, cryptosporidiosis, giardiasis, chlamydial diseases, leishmaniasis, toxocariasis, filariasis, and more. The company emphasizes research and development, producing innovative diagnostic solutions and collaborating on new product development. It has expanded its portfolio to include rapid diagnostic tests, water testing products, and standards for malaria diagnostics, including the first Pf-HRP2 standard for quantitative assays. Cellabs maintains strong relationships with sister companies like TropBio Pty Ltd, producing complementary diagnostics such as the WHO-recommended Og4C3 Filariasis Ag ELISA. The company is committed to quality manufacturing standards, ISO13485 compliance, and providing reliable, sensitive, and easy-to-use diagnostic tools for global health challenges.
Industries
Nr. of Employees
small (1-50)
Cellabs
7/27 Dale Street Brookvale 2100 SYDNEY NSW, AUSTRALIA
Products
Malaria antigen and antibody ELISA assays
Plate‑based ELISA kits for detection and quantification of malaria antigens (such as HRP2 and pLDH) and anti‑Plasmodium antibodies; offered in multiple plate formats and throughput options for clinical, research and surveillance use.
Immunofluorescent assay kits for parasite detection
Direct and indirect immunofluorescent assay kits for detection and morphological differentiation of parasites (including Cryptosporidium and Giardia) in faecal, water and environmental samples; compatible with fluorescence microscopy workflows.
Rapid staining reagents for water testing
Short‑protocol staining reagents for detection of waterborne parasites with options for counterstain formulations and concentrated reagent formats for specialised methods.
Filariasis antigen and antibody ELISAs
ELISA assays for detection of filariasis antigens and antibodies, validated for serum, whole blood and dried blood spot samples and intended for sentinel surveillance and program evaluation.
Filter paper blood collection devices
Filter paper / disk devices for finger‑prick blood collection to support field sampling, transport and storage for laboratory testing and surveillance studies.
Recombinant antigen‑based ELISAs for multiple pathogens
ELISA kits using recombinant antigens to improve specificity for a range of infectious agents; available in research‑use formats and variants intended for regulatory submission where indicated.
Malaria antigen and antibody ELISA assays
Plate‑based ELISA kits for detection and quantification of malaria antigens (such as HRP2 and pLDH) and anti‑Plasmodium antibodies; offered in multiple plate formats and throughput options for clinical, research and surveillance use.
Immunofluorescent assay kits for parasite detection
Direct and indirect immunofluorescent assay kits for detection and morphological differentiation of parasites (including Cryptosporidium and Giardia) in faecal, water and environmental samples; compatible with fluorescence microscopy workflows.
Rapid staining reagents for water testing
Short‑protocol staining reagents for detection of waterborne parasites with options for counterstain formulations and concentrated reagent formats for specialised methods.
Filariasis antigen and antibody ELISAs
ELISA assays for detection of filariasis antigens and antibodies, validated for serum, whole blood and dried blood spot samples and intended for sentinel surveillance and program evaluation.
Filter paper blood collection devices
Filter paper / disk devices for finger‑prick blood collection to support field sampling, transport and storage for laboratory testing and surveillance studies.
Recombinant antigen‑based ELISAs for multiple pathogens
ELISA kits using recombinant antigens to improve specificity for a range of infectious agents; available in research‑use formats and variants intended for regulatory submission where indicated.
Services
End‑to‑end assay design, prototype development and optimisation for infectious disease targets, delivered on a contract or collaborative basis.
Analytical performance evaluations and stability studies for prototype assays to generate validation and shelf‑life data suitable for product development and regulatory submissions.
Process development services to translate laboratory assay methods into manufacturing‑ready processes and documentation for higher volume production and integration with quality management systems.
Development and provision of calibrated antigen reference materials and positive controls to support quantitative antigen assays and assay standardisation.
End‑to‑end assay design, prototype development and optimisation for infectious disease targets, delivered on a contract or collaborative basis.
Analytical performance evaluations and stability studies for prototype assays to generate validation and shelf‑life data suitable for product development and regulatory submissions.
Process development services to translate laboratory assay methods into manufacturing‑ready processes and documentation for higher volume production and integration with quality management systems.
Development and provision of calibrated antigen reference materials and positive controls to support quantitative antigen assays and assay standardisation.
Expertise Areas
- Immunodiagnostic assay development for infectious and tropical diseases
- Parasitology diagnostics and microscopy‑based detection
- Serology and antigen detection for clinical, surveillance and blood‑screening use
- Assay prototyping, analytical validation and stability testing
Key Technologies
- Enzyme‑linked immunosorbent assay (ELISA)
- Direct and indirect immunofluorescence assays
- Lateral‑flow immunochromatographic rapid tests
- Monoclonal antibody reagents
News & Updates
Cellabs is developing a high-quality COVID-19 antibody test kit in response to the pandemic.
Cellabs is transitioning its EU CE Marking regulatory compliance to the new IVDR by 2021.
Cellabs has developed the first standard for Pf-HRP2 for quantitative malaria assays, calibrated against recombinant antigen, supporting malaria research and diagnostics.
Cellabs is developing a high-quality COVID-19 antibody test kit in response to the pandemic.
Cellabs is transitioning its EU CE Marking regulatory compliance to the new IVDR by 2021.
Cellabs has developed the first standard for Pf-HRP2 for quantitative malaria assays, calibrated against recombinant antigen, supporting malaria research and diagnostics.